MedTrace Logo

A Study to Evaluate the Safety of Neural Stem Cells in Patients With Parkinson's Disease

NCT02452723 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-01-20

No results posted yet for this study

Summary

This study will evaluate the safety of an investigational cell transplantation therapy, ISC-hpNSC, in patients with Parkinson's disease. All patients will receive the therapy, which consists of human neural stem cells. Three dose levels will be examined in the study.

Conditions

  • Parkinson Disease

Interventions

BIOLOGICAL

ISC-hpNSC

Sponsors & Collaborators

  • Cyto Therapeutics Pty Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2025-06-18
Completion
2025-09-01

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02452723 on ClinicalTrials.gov